Compass Therapeutics, Inc. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that Compass Therapeutics, Inc. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Net Income — By Quarter
| Quarter | Fiscal Year | Period End | Value | Filed |
|---|---|---|---|---|
| Q3 | 2025 | Sep 30, 2025 | ($14.26M) | Nov 5, 2025 |
| Q2 | 2025 | Jun 30, 2025 | ($19.88M) | Aug 11, 2025 |
| Q3 | 2025 | Jun 30, 2025 | ($19.88M) | Nov 5, 2025 |
| Q2 | 2025 | Mar 31, 2025 | ($16.63M) | Aug 11, 2025 |
| Q3 | 2025 | Mar 31, 2025 | ($16.63M) | Nov 5, 2025 |
| Q1 | 2025 | Mar 31, 2025 | ($16.63M) | May 8, 2025 |
| Q3 | 2025 | Sep 30, 2024 | ($10.48M) | Nov 5, 2025 |
| Q2 | 2025 | Jun 30, 2024 | ($13.08M) | Aug 11, 2025 |
| Q3 | 2025 | Jun 30, 2024 | ($13.08M) | Nov 5, 2025 |
| Q3 | 2025 | Mar 31, 2024 | ($10.79M) | Nov 5, 2025 |
| Q1 | 2025 | Mar 31, 2024 | ($10.79M) | May 8, 2025 |
| Q2 | 2025 | Mar 31, 2024 | ($10.79M) | Aug 11, 2025 |
| Q3 | 2024 | Sep 30, 2023 | ($9.96M) | Nov 12, 2024 |
| Q3 | 2024 | Jun 30, 2023 | ($11.28M) | Nov 12, 2024 |
| Q2 | 2024 | Jun 30, 2023 | ($11.28M) | Aug 12, 2024 |
| Q3 | 2024 | Mar 31, 2023 | ($7.84M) | Nov 12, 2024 |
| Q1 | 2024 | Mar 31, 2023 | ($7.84M) | May 13, 2024 |
| Q2 | 2024 | Mar 31, 2023 | ($7.84M) | Aug 12, 2024 |
| Q3 | 2023 | Sep 30, 2022 | ($11.98M) | Nov 9, 2023 |
| Q2 | 2023 | Jun 30, 2022 | ($8.49M) | Aug 3, 2023 |
Operating Income — By Quarter
| Quarter | Fiscal Year | Period End | Value | Filed |
|---|---|---|---|---|
| Q3 | 2025 | Sep 30, 2025 | ($15.82M) | Nov 5, 2025 |
| Q2 | 2025 | Jun 30, 2025 | ($21.07M) | Aug 11, 2025 |
| Q1 | 2025 | Mar 31, 2025 | ($17.97M) | May 8, 2025 |
| Q3 | 2025 | Sep 30, 2024 | ($12.24M) | Nov 5, 2025 |
| Q2 | 2025 | Jun 30, 2024 | ($15.05M) | Aug 11, 2025 |
| Q1 | 2025 | Mar 31, 2024 | ($12.77M) | May 8, 2025 |
| Q3 | 2024 | Sep 30, 2023 | ($11.93M) | Nov 12, 2024 |
| Q2 | 2024 | Jun 30, 2023 | ($13.34M) | Aug 12, 2024 |
| Q1 | 2024 | Mar 31, 2023 | ($9.71M) | May 13, 2024 |
| Q3 | 2023 | Sep 30, 2022 | ($12.60M) | Nov 9, 2023 |
| Q2 | 2023 | Jun 30, 2022 | ($8.99M) | Aug 3, 2023 |
| Q1 | 2023 | Mar 31, 2022 | ($7.18M) | May 4, 2023 |
| Q3 | 2022 | Sep 30, 2021 | ($5.85M) | Nov 9, 2022 |
| Q2 | 2022 | Jun 30, 2021 | ($55.69M) | Aug 1, 2022 |
| Q1 | 2022 | Mar 31, 2021 | ($7.34M) | May 9, 2022 |
| Q3 | 2021 | Sep 30, 2020 | ($8.96M) | Nov 12, 2021 |
| Q2 | 2021 | Jun 30, 2020 | ($5.07M) | Aug 16, 2021 |
| Q1 | 2021 | Mar 31, 2020 | ($5.83M) | Apr 30, 2021 |
| Q3 | 2020 | Dec 31, 2019 | ($10.2K) | Feb 14, 2020 |
| Q3 | 2020 | Sep 30, 2019 | ($8.38M) | Nov 9, 2020 |